Opinion

Video

Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria 

Author(s):

Brian Keegan, MD, PhD,Giselle Mosnaim, MD

A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU.

Video content above is prompted by the following question(s):

  • Which healthcare specialties are involved in managing patients with CSU, and how can multidisciplinary care be optimized?
  • What are the comorbidities that are most seen in patients with CSU, and how do these affect your management plan?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr John Mascarenhas
5 experts are featured in this series
2 experts in this video
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
Related Content
Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com
June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa
Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan
Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Marginal zone lymphoma | Image: Atlas of Hematological Cytology
June 24th 2025

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

Mary Caffrey
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Myasthenia gravis diagnosis | Image Credit: Maggie L. Shaw/sora.chatgpt.com
June 19th 2025

RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

Abigail Lewis
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo